These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6221750)

  • 21. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
    Jung A
    Am J Med; 1982 Feb; 72(2):221-6. PubMed ID: 6460442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.
    Delmas PD; Charhon S; Chapuy MC; Vignon E; Briancon D; Edouard C; Meunier PJ
    Metab Bone Dis Relat Res; 1982; 4(3):163-8. PubMed ID: 6218370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
    Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
    Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with clodronate in patients with hypercalcemia secondary to malignancy.
    Lind L; Wengle B; Ljunghall S
    Ups J Med Sci; 1987; 92(3):259-63. PubMed ID: 2966487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate.
    Siris ES; Grossbard L; Halper JP; Blume RS; Jacobs TP
    Metab Bone Dis Relat Res; 1983-1984; 5(2):61-3. PubMed ID: 6231452
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
    Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
    Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of painful bone lesions and hypercalcemia.
    Ascari E; Attardo-Parrinello G; Merlini G
    Eur J Haematol Suppl; 1989; 51():135-9. PubMed ID: 2534078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
    Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy.
    Merlini G; Parrinello GA; Piccinini L; Crema F; Fiorentini ML; Riccardi A; Pavesi F; Novazzi F; Silingardi V; Ascari E
    Hematol Oncol; 1990; 8(1):23-30. PubMed ID: 2137106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypercalcaemia in a 63 year old man.
    Ranganath L; Semple MJ
    Postgrad Med J; 2000 May; 76(895):309-10, 313-4. PubMed ID: 10775292
    [No Abstract]   [Full Text] [Related]  

  • 34. [Suppression of severe hypocalcemia associated with malignant lymphoma by intravenous administration of dichloromethylene diphosphonate].
    Tschopp JM; Jung A; Miescher PA
    Schweiz Med Wochenschr; 1981 Oct; 111(44):1655-7. PubMed ID: 6458087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug treatment of primary hyperparathyroidism: use of clodronate disodium.
    Douglas DL; Kanis JA; Paterson AD; Beard DJ; Cameron EC; Watson ME; Woodhead S; Williams J; Russell RG
    Br Med J (Clin Res Ed); 1983 Feb; 286(6365):587-90. PubMed ID: 6218861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone.
    Kanis JA; Preston CJ; Beard DJ; Beneton M; Harris S; Russell RG
    Bone; 1985; 6(2):69-72. PubMed ID: 2409999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of hypercalcemia of myelomatous origin with intravenous diphosphonates].
    Charhon S; Chapuy MC; Valentin-Opran A; Edouard C; Rosini S; Meunier PJ
    Presse Med; 1983 Dec; 12(47):2983-6. PubMed ID: 6228888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
    Yates AJ; Percival RC; Gray RE; Atkins RM; Urwin GH; Hamdy NA; Preston CJ; Beneton MN; Russell RG; Kanis JA
    Lancet; 1985 Jun; 1(8444):1474-7. PubMed ID: 2861411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease.
    Harris ST; Neer RM; Segre GV; Petkau AJ; Tully GL; Daly M; Potts JT
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1100-7. PubMed ID: 6215419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.